Withdrawal syndrome is not precipitated when butorphanol is added to opiate or opioid therapy. A comment on intranasal butorphanol-induced apraxia reversed by naloxone.
Department of Anesthesiology, Rush Medical College, Rush University, Chicago, Illinois, USA.
R L
RL
Barkin
D000701:Analgesics, Opioid / Q000009:adverse effects*; D001072:Apraxias / Q000139:chemically induced* / Q000188:drug therapy; D002077:Butorphanol / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D009292:Narcotic Antagonists / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D002077:Butorphanol